Skip to content

Total Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$19.8B+55.5%
Pfizer logo
PfizerPFE
$14.45B+5.4%
Rogers Corporation logo
Rogers CorporationROG
$200.5M+5.2%
Amgen logo
AmgenAMGN
$8.62B+5.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$3.61B+19.0%
Incyte logo
IncyteINCY
$1.27B+20.9%

Segments

By product

See full
Grant$15K-97.7%

Other financials

Income statement

See full
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.59B+75.2%
Enterprise value$2.55B+74.4%
P/S2,989.2×+2,794×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's total revenue?
Celldex Therapeutics (CLDX) reported total revenue of $15K in Q1 2026.
How has Celldex Therapeutics's total revenue changed year-over-year?
Celldex Therapeutics's total revenue decreased by 97.8% year-over-year, from $695K to $15K.
What is the long-term trend for Celldex Therapeutics's total revenue?
Over 4 years (2021 to 2025), Celldex Therapeutics's total revenue has grown at a -24.1% compound annual growth rate (CAGR), from $4.65M to $1.55M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.